Enveric Biosciences (NASDAQ:ENVB) announced that Bob Dagher will be joining the company as its chief medical officer.
The psychedelic company said that Dagher brings over 20 years of experience working in clinical development in the pharmaceutical industry for both small and large pharmaceutical companies and as a board-certified physician from the American Board of neurology and psychiatry.
Dagher has supported and driven successful drug development programs from preclinical stages through Phase 4 clinical trials.
READ: Enveric Biosciences announces positive preclinical data for its CBD-based product EV102 treating radiodermatitis
"Dr. Dagher joins our team at a crucial time where we are continuing to build momentum and drive development of our key psychedelic molecules for the mind and cannabinoids for the body," said Joseph Tucker, CEO of Enveric Biosciences (NASDAQ:ENVB).
He added: "Dr. Dagher brings extensive experience working in the pharmaceutical industry with a focus and passion for drug development for neurological and mental health indications. His experience is expected to be very valuable as he will lead Enveric alongside our clinical team in continuing to advance our pipeline.”
Prior to joining Enveric, Dagher served as the chief medical officer at WCG MedAvante-ProPhase where he led the clinical science organization to help forge and develop compelling scientific solutions to match industry challenges.
Before joining WCG, Dagher served as the chief medical officer at Cadent Therapeutics, where he led and advanced the company's pipeline of small molecules, coupled with the implementation of precision biomarkers, for the development of innovative programs in rare diseases and common indications targeting movement and cognitive disorders.
"As a trailblazing company working to discover and develop the next-generation treatments through the use of both psychedelic-derived molecules for the mind and synthetic cannabinoids for the body, Enveric has major potential to make a real difference for mental health and cancer patients in need," said Dagher.
Robert Wilkins stepped down from his role of chief medical officer on November 29th, 2021.
Enveric is an innovative biotechnology company developing next-generation mental health and oncology treatments and clinical discovery platform, leveraging psychedelic-derived molecules for the mind and synthetic cannabinoids for the body.
Contact Ritika at ritika@proactiveinvestors.com